EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS

Аbstract. Сlinical and immunocorrective efficiency of Roncoleukin® (IL-2) monotherapy applied as subcutaneous injections versus inhalatory mode of treatment, was studied in patients with chronic recurrent infections. It was shown that administration of Roncoleukin® at a total dose of 1.5 m...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	O. I. Zheltova, N. M. Starostina, M. A. Tikhonova, O. Yu. Leplina, E. R. Chernykh, A. A. Ostanin
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2014
Materias:	cytokine balance regulatory t-cells cytokine therapy il-2 recurrent infections Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/cff50ac638bf4de78a946b0819458c87
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cff50ac638bf4de78a946b0819458c87
record_format	dspace
spelling	oai:doaj.org-article:cff50ac638bf4de78a946b0819458c872021-11-18T08:03:41ZEFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS1563-06252313-741X10.15789/1563-0625-2011-2-3-227-236https://doaj.org/article/cff50ac638bf4de78a946b0819458c872014-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/454https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XАbstract. Сlinical and immunocorrective efficiency of Roncoleukin® (IL-2) monotherapy applied as subcutaneous injections versus inhalatory mode of treatment, was studied in patients with chronic recurrent infections. It was shown that administration of Roncoleukin® at a total dose of 1.5 mg was accompanied by increased activity of Th1 lymphocytes and reduced in vitro production of IL-10, and does not exert any adverse immunotropic effects associated with Treg expansion. In general, the positive clinical effect was registered in 65% (26/40) of the patients, and its duration ranged between 3 and 7 months (a mean of 4.4±0.2 months). Clinical efficiency of Roncoleukin® inhalations proved to be not inferior to conventional Roncoleukin® immunotherapy performed by subcutaneous injections (resp., 70 and 60% of positive responses), and allows a more significant prolongation of event-free remission. (Med. Immunol., 2011, vol. 13, N 2-3, pp 227-236)O. I. ZheltovaN. M. StarostinaM. A. TikhonovaO. Yu. LeplinaE. R. ChernykhA. A. OstaninSPb RAACIarticlecytokine balanceregulatory t-cellscytokine therapyil-2recurrent infectionsImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 13, Iss 2-3, Pp 227-236 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	cytokine balance regulatory t-cells cytokine therapy il-2 recurrent infections Immunologic diseases. Allergy RC581-607
spellingShingle	cytokine balance regulatory t-cells cytokine therapy il-2 recurrent infections Immunologic diseases. Allergy RC581-607 O. I. Zheltova N. M. Starostina M. A. Tikhonova O. Yu. Leplina E. R. Chernykh A. A. Ostanin EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS
description	Аbstract. Сlinical and immunocorrective efficiency of Roncoleukin® (IL-2) monotherapy applied as subcutaneous injections versus inhalatory mode of treatment, was studied in patients with chronic recurrent infections. It was shown that administration of Roncoleukin® at a total dose of 1.5 mg was accompanied by increased activity of Th1 lymphocytes and reduced in vitro production of IL-10, and does not exert any adverse immunotropic effects associated with Treg expansion. In general, the positive clinical effect was registered in 65% (26/40) of the patients, and its duration ranged between 3 and 7 months (a mean of 4.4±0.2 months). Clinical efficiency of Roncoleukin® inhalations proved to be not inferior to conventional Roncoleukin® immunotherapy performed by subcutaneous injections (resp., 70 and 60% of positive responses), and allows a more significant prolongation of event-free remission. (Med. Immunol., 2011, vol. 13, N 2-3, pp 227-236)
format	article
author	O. I. Zheltova N. M. Starostina M. A. Tikhonova O. Yu. Leplina E. R. Chernykh A. A. Ostanin
author_facet	O. I. Zheltova N. M. Starostina M. A. Tikhonova O. Yu. Leplina E. R. Chernykh A. A. Ostanin
author_sort	O. I. Zheltova
title	EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS
title_short	EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS
title_full	EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS
title_fullStr	EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS
title_full_unstemmed	EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS
title_sort	efficiency of roncoleukin® in treatment of chronic recurrent infections
publisher	SPb RAACI
publishDate	2014
url	https://doaj.org/article/cff50ac638bf4de78a946b0819458c87
work_keys_str_mv	AT oizheltova efficiencyofroncoleukinintreatmentofchronicrecurrentinfections AT nmstarostina efficiencyofroncoleukinintreatmentofchronicrecurrentinfections AT matikhonova efficiencyofroncoleukinintreatmentofchronicrecurrentinfections AT oyuleplina efficiencyofroncoleukinintreatmentofchronicrecurrentinfections AT erchernykh efficiencyofroncoleukinintreatmentofchronicrecurrentinfections AT aaostanin efficiencyofroncoleukinintreatmentofchronicrecurrentinfections
_version_	1718422510146420736

EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS

Ejemplares similares